LifeStance Health Group, Inc. Form 4 Filings

LifeStance Health Group, Inc. (LFST) reported that Chief Executive Officer and director David Bourdon transferred 150,000 shares of common stock on September 2, 2026 in an "other acquisition or disposition" transaction. According to the disclosure, the shares were transferred to a family member for no value for estate planning purposes, and Bourdon now holds 1,248,247 shares directly.

LifeStance Health Group, Inc. (LFST) reported that Chief Technology Officer Vukasin Paunovich sold 42,067 shares of common stock on September 2, 2026 in a sale characterized as an open market or private transaction at a weighted average price of $12.87 per share, with individual trades ranging from $12.86 to $12.905. After this transaction, he directly owned 205,379 shares of LifeStance common stock.

LifeStance Health Group, Inc. (LFST) reported that Chief People Officer Ann Varanakis had 8,156 shares of common stock withheld on August 24, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The shares were valued at $12.16 per share and were not sold in the open market, leaving her with 413,881 shares held directly after the transaction.

LifeStance Health Group, Inc. (LFST) director Teresa DeLuca reported selling 7,500 shares of common stock on 2026-08-14 at a weighted average price of $12.68 per share, in multiple trades between $12.68 and $12.695. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units and does not represent a discretionary trade. Following this sale, DeLuca directly holds 97,093 shares of LifeStance common stock.

LifeStance Health Group, Inc. director Teresa DeLuca reported a sale of common stock. On 2026-08-13, she sold 20,441 shares of common stock at a reported price of $12.23 per share in a sale characterized as an open market or private transaction. Following this transaction, she directly holds 104,593 shares of LifeStance Health Group common stock.

LifeStance Health Group, Inc. director Kenneth A. Burdick reported a sale of 500,000 shares of common stock on 2026-08-11 at a weighted average price of $11.51 per share, with individual trades between $11.50 and $11.665. Following this sale, he directly holds 2,970,810 shares and indirectly holds 46,511 shares through Burdick Family LLC.

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported selling 44,394 shares of common stock on August 10, 2026, at $10.85 per share in an open market or private transaction. After this transaction, he directly holds 247,446 shares. The transaction is flagged as made pursuant to a Rule 10b5-1 trading plan, indicating it was executed under a pre-arranged plan.

LifeStance Health Group, Inc. reported that entities associated with TPG sold 13,643,207 shares of Common Stock at $10.62 per share in an indirect transaction. After this sale, TPG VIII Lynnwood Holdings Aggregation, L.P. directly holds 98,101,407 LifeStance common shares. The reporting persons are treated as indirect holders through a multi‑entity ownership chain and each disclaims beneficial ownership beyond any pecuniary interest.

LifeStance Health Group, Inc. reported that Chief Operating Officer Lisa K. Miller sold 47,912 shares of common stock on August 10, 2026 at $10.85 per share in an open-market or private transaction. After this sale, she directly holds 281,289 shares of LifeStance common stock. The transaction was affirmed as being made pursuant to a Rule 10b5-1 trading plan.

LifeStance Health Group, Inc. director Kenneth A. Burdick reported an equity award under which he acquired 45,495 shares of common stock at $0.0000 per share, characterized as a grant or award acquisition. Following this award, he reports 3,470,810 shares held directly and 46,511 shares held indirectly through Burdick Family LLC. His reported holdings include 45,495 restricted stock units, each representing a contingent right to receive one share of common stock.

Palmer Eric P reported acquisition or exercise transactions in this Form 4 filing.

LifeStance Health Group, Inc. director Eric P. Palmer received an equity award of 17,746 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and increases his directly held position to 89,174 shares, including these RSUs, which each represent a contingent right to one share of common stock.

Bessler Robert reported acquisition or exercise transactions in this Form 4 filing.

LifeStance Health Group director Robert Bessler reported a new equity award and updated holdings. He received 17,746 restricted stock units, each representing one share of common stock, at a price of $0.00 per share, increasing his direct holdings to 75,365 common shares, including these RSUs.

He also reports indirect ownership positions in several entities: 36,363 common shares held by Alpine Glow Capital, 656,560 common shares held by Shama LLC, and 539,763 common shares held by Vitthal LLC. In each case, he disclaims beneficial ownership beyond his pecuniary interest.

LifeStance Health Group, Inc. director Sarah Personette received an equity grant of common stock. She acquired 17,746 shares at a stated price of $0.00 per share as a grant, increasing her direct holdings to 92,512 shares of common stock.

The grant includes 17,746 restricted stock units (RSUs), and each RSU represents a contingent right to receive one share of LifeStance common stock. This is a compensation-related award rather than an open-market purchase.

LifeStance Health Group director Teresa DeLuca received an equity grant. She acquired 17,746 shares of common stock in the form of restricted stock units (RSUs), which are rights to receive one share of common stock per unit at no cash cost. After this award, she directly holds 125,034 shares of the company’s common stock, indicating a larger equity stake aligned with shareholder interests through stock-based compensation rather than open-market purchases or sales.

LifeStance Health Group, Inc. director Justice Thurman reported receiving an award of 35,492 shares of common stock in the form of restricted stock units (RSUs) on July 2, 2026. The RSU grant was recorded at a price of $0.00 per share, reflecting a compensation-related acquisition rather than an open-market purchase. Following this award, Thurman directly holds 35,492 RSUs, each representing a contingent right to receive one share of LifeStance common stock.

LifeStance Health Group, Inc. director Lori Goltermann reported an equity compensation award. On July 2, 2026, she acquired 35,492 shares of common stock at $0.00 per share through a grant classified as restricted stock units (RSUs). Following this award, she directly holds 35,492 shares, all represented by RSUs, each of which entitles her to receive one share of LifeStance common stock if vesting conditions are met.

LifeStance Health Group director-related entities sold a sizable block of shares. On June 26, 2026, entities associated with director Robert Bessler — Shama LLC and Vitthal LLC — executed open-market sales totaling 894,337 shares of LifeStance common stock at a weighted average price of $10.13 per share.

The filing states these sales occurred in multiple transactions within a price range of $10.00 to $10.295 per share. After these transactions, Shama LLC held 656,560 shares and Vitthal LLC held 539,763 shares of common stock. The report also shows Bessler with 57,619 shares held directly and 36,363 shares held indirectly in a separate position. Footnotes emphasize that he disclaims beneficial ownership of certain securities except to the extent of his pecuniary interest.

LifeStance Health Group’s Chief Technology Officer, Vukasin Paunovich, reported a tax-related share withholding tied to vested restricted stock units. On June 11, 2026, 17,456 shares of common stock were withheld by the company at $8.61 per share to cover tax obligations, and this was not an open-market sale. After this net settlement, Paunovich directly holds 291,840 shares of LifeStance common stock.

LifeStance Health Group director Robert Bessler reported indirect open-market sales of company stock by entities associated with him. On May 12, 2026, Shama LLC and Vitthal LLC each sold 287,517 shares of LifeStance common stock at $8.02 per share, for a total of 575,034 shares.

After these transactions, Shama LLC held 1,103,729 shares and Vitthal LLC held 986,931 shares. Separate holding entries show 57,619 shares held directly by Bessler and 36,363 shares held indirectly. Footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

LifeStance Health Group director Eric Shuey reported an indirect share sale through a family trust. On this Form 4, the Eric Shuey Gift Trust completed an open-market sale of 243,362 shares of LifeStance common stock at a price of $8.02 per share. Following the transaction, the trust held 867,562 shares indirectly, while Shuey also reported 93,982 shares held directly. The filing notes that Shuey disclaims beneficial ownership of the trust-held securities except to the extent of his pecuniary interest.

LifeStance Health Group, Inc. director Darren M. Black reported an indirect open-market sale of 5,899,661 shares of Common Stock at $8.02 per share through Summit Partners–affiliated investment entities. After these transactions, the filing shows these entities holding 23,310,115 shares in total. The shares are held across several Summit funds, and the footnotes state that Summit Partners, L.P., via an investment committee that includes Black, has voting and dispositive power while each person and fund disclaims beneficial ownership except to the extent of pecuniary interest.

LifeStance Health Group, Inc. reported that an entity affiliated with TPG completed an open-market sale of 28,281,943 shares of Common Stock at $8.02 per share. After this transaction, TPG VIII Lynnwood Holdings Aggregation, L.P. continues to hold 111,744,614 shares indirectly, with the reporting persons only deemed beneficial owners to the extent of their pecuniary interests.

LifeStance Health Group director Robert Bessler reported open-market sales of LifeStance Health Group, Inc. common stock through entities associated with him. Shama LLC and Vitthal LLC each sold 37,500 shares at a weighted average price of $8.55 per share, in transactions ranging from $8.40 to $8.89. After these sales, Shama LLC held 1,353,746 shares and Vitthal LLC held 1,236,948 shares. Bessler also reported 57,619 shares held directly and 36,363 shares held by Alpine Glow Capital. Footnotes state that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

LifeStance Health Group, Inc. director Robert Bessler reported open-market sales of LifeStance common stock through entities he is associated with. On April 24, Shama LLC sold 31,074 shares and Vitthal LLC sold 31,073 shares at a reported price of $7.05 per share. On April 23, Shama LLC and Vitthal LLC each sold 3,876 shares at a reported price of $7.00 per share.

After these transactions, reported indirect holdings included 1,391,246 shares through Shama LLC, 1,274,448 shares through Vitthal LLC and 36,363 shares held of record by Alpine Glow Capital, plus 57,619 shares held directly. The footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

LifeStance Health Group, Inc. director Robert Bessler reported open-market sales of company common stock on April 21, 2026 through entities he is associated with. Shama LLC sold 2,550 shares and Vitthal LLC sold 2,551 shares at a weighted average price of $7.01 per share, within a range of $7.00 to $7.02.

After these sales, Shama LLC held 1,426,196 shares and Vitthal LLC held 1,309,397 shares of LifeStance common stock. Separate entries show 36,363 shares held indirectly, described as held by Alpine Glow Capital, and 57,619 shares held directly by Bessler. The reporting person disclaims beneficial ownership of the LLC- and Alpine Glow-held shares except to the extent of his pecuniary interest.

LifeStance Health Group director and officer Ryan Pardo reported a routine tax-related share withholding tied to vesting equity. On April 1, 2026, 9,376 shares of common stock were withheld at $6.37 per share to cover tax obligations from restricted stock units that vested on March 9, 2026. The filing states this was not an open-market sale. After the withholding, Pardo directly held 1,093,366 shares, and an additional 2,551,520 shares were reported as held indirectly by a trust, with beneficial ownership of those trust shares disclaimed except for his pecuniary interest.

LifeStance Health Group, Inc. officer Ryan McGroarty reported a Form 4 showing 24,255 shares of common stock withheld at $6.45 per share to cover tax obligations when restricted stock units vested on March 24, 2026. These withheld shares were not sold on the open market. After the transaction, McGroarty directly holds 772,235 shares of common stock.

LifeStance Health Group, Inc. reported that company officer Ryan McGroarty had restricted stock units vest on March 17, 2026, and 47,594 shares of common stock were withheld at $6.89 per share to cover tax obligations. The filing states this was not an open-market sale. After the withholding, McGroarty directly holds 796,490 shares of LifeStance common stock.

LifeStance Health Group director Kenneth A. Burdick reported compensation-related stock movements on March 9, 2026. He acquired common stock through vested restricted stock units and performance-based restricted stock units, with two grant or award acquisitions totaling 740,504 shares at a stated price of $0.00 per share.

To cover tax withholding obligations on these RSUs and PSUs, the issuer withheld 327,209 shares at $6.91 per share in three separate dispositions, which the footnotes clarify were not open-market sales. Following these transactions, Burdick directly held 3,425,315 shares, with an additional 46,511 shares held indirectly through Burdick Family LLC.

LifeStance Health Group, Inc. Chief Executive Officer David Bourdon reported stock-based compensation activity rather than open-market trading. On March 9, 2026, previously granted restricted stock units (RSUs) and performance-based restricted stock units (PSUs) vested, resulting in share awards recorded as acquisitions.

To cover tax withholding obligations tied to the vesting and net settlement of these RSUs and PSUs, the company withheld a total of 148,382 shares at a reported price of $6.91 per share across several transactions. The footnotes state these withholdings simply reduced the shares delivered to him and did not involve any open-market sales.

LifeStance Health Group, Inc. Chief Operating Officer Lisa K. Miller reported equity compensation activity involving restricted stock units and related tax withholding. On March 9, 2026, she acquired 26,836 shares of common stock at a stated price of $0.00 per share in a grant/award tied to vested performance-based restricted stock units previously granted on March 6, 2025.

On the same date, the issuer withheld 14,766 shares of common stock at $6.91 per share to satisfy tax obligations for vested RSUs and separately withheld 13,446 shares at $6.91 per share for tax obligations related to vested PSUs. Footnotes specify these withheld shares reduce the shares issued to Miller and do not constitute any open-market sale. After these transactions, she directly owned 329,201 shares of common stock.

LifeStance Health Group Chief People Officer Ann Varanakis reported compensation-related share activity in connection with vested restricted stock units (RSUs) and performance-based RSUs (PSUs) on March 9, 2026.

She acquired 26,836 and 59,789 shares of common stock at $0.00 per share through RSU and PSU settlements. To cover tax withholding obligations on these vestings, the issuer withheld a total of 44,963 shares at a reference price of $6.91 per share. The footnotes state these withholdings reduce shares delivered and do not involve any open-market sales. Following these transactions, Varanakis directly holds 422,037 shares of LifeStance common stock.

LifeStance Health Group director and officer Ryan Pardo reported equity compensation vesting and related tax withholding transactions in Common Stock. On March 9, 2026, he received stock awards of 40,254 and 105,711 shares at no cost as restricted and performance-based units vested.

To cover tax obligations on these vestings, the issuer withheld 12,280, 15,841, and 38,479 shares at $6.91 per share, which the footnotes state are not open-market sales. Following these transactions, Pardo directly owned 1,102,742 shares and had indirect exposure to 2,551,520 shares held by the Kimberly Pardo Irrevocable Trust, where he disclaims beneficial ownership beyond any pecuniary interest.

LifeStance Health Group, Inc. executive Ryan McGroarty reported equity compensation activity involving performance-based restricted stock units (PSUs) that vested on March 9, 2026. He acquired 127,878 shares of common stock from PSUs granted on March 17, 2025, and 65,168 shares from PSUs granted on March 24, 2025.

To cover tax withholding obligations on these PSU settlements, the issuer withheld 50,929 shares and 25,644 shares at a price of $6.91 per share. The footnotes state these withholdings reduced the shares delivered on vesting and did not involve any open-market sales.

After these transactions, McGroarty directly held 844,084 shares of LifeStance common stock.

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported equity compensation activity tied to performance-based restricted stock units. On March 9, 2026, he acquired 62,935 shares of common stock at $0.00 per share upon vesting of previously granted PSUs. On the same date, 18,541 shares were withheld at $6.91 per share to satisfy tax withholding obligations, which the company notes did not involve any open-market sale. Following these transactions, Paunovich directly holds 309,296 shares of common stock.

LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units. On March 5, 2026, she was granted 115,107 RSUs, each representing a contingent right to receive one share of LifeStance common stock.

The Form 4 classifies this as a grant or award acquisition at a price of $0.00 per share, typical for stock-based compensation. Following this grant, her directly held common stock and RSU-related interest totals 115,107 shares of LifeStance common stock on a contingent basis.

LifeStance Health Group, Inc. officer Ryan Pardo reported equity award activity in the company’s common stock. On March 5, 2026, he acquired 129,496 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.

On March 6, 2026, 21,854 shares were withheld at $6.93 per share to cover tax obligations related to vested RSUs. The filing specifies that these withheld shares reduce the shares issued to him and do not constitute any open‑market sale.

After these transactions, he held 1,023,377 shares directly and 2,551,520 shares indirectly through the Kimberly Pardo Irrevocable Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

LifeStance Health Group, Inc. reported insider equity activity by its Chief Executive Officer, David Bourdon. On March 5, 2026, he acquired 395,683 shares of common stock through a grant of restricted stock units, with each RSU representing the right to receive one common share.

On March 6, 2026, 65,837 shares of common stock were withheld by the company at a price of $6.93 per share to cover tax obligations from vested RSUs. The footnote explains this was a tax-withholding disposition and did not involve any open-market sale of shares.

LifeStance Health Group director Kenneth A. Burdick reported a tax-related share withholding tied to vested restricted stock units. On March 6, 2026, the issuer withheld 424,551 shares of common stock at $7.11 per share to cover tax obligations, which the filing states is not an open-market sale. After this net settlement, Burdick directly holds 3,012,020 shares and indirectly holds 46,511 shares through Burdick Family LLC.

Paunovich Vukasin reported acquisition or exercise transactions in this Form 4 filing.

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich was granted 86,331 shares of common stock in the form of restricted stock units (RSUs) on March 5, 2026. Each RSU represents a right to receive one share of common stock, increasing his directly held stake to 264,902 shares after the award.

LifeStance Health Group, Inc. reported that officer Lisa K. Miller received an equity grant of 107,914 restricted stock units on March 5, 2026. Each RSU represents a contingent right to receive one share of common stock.

On March 6, 2026, 21,590 shares of common stock were withheld by the company at $6.93 per share to cover tax obligations related to vested RSUs. The footnote states this was not an open-market sale but a reduction in shares issued upon settlement. After these transactions, Miller directly held 330,577 shares of common stock.

LifeStance Health Group, Inc. Chief People Officer Ann Varanakis reported two equity transactions in company common stock. On March 5, 2026, she acquired 86,331 restricted stock units as a grant, each representing a contingent right to receive one share of common stock.

On March 6, 2026, 21,566 shares were withheld by the company at a price of $6.93 per share to cover tax obligations upon settlement of vested RSUs. The footnote states this withholding reduced shares delivered to her and did not involve any open‑market sale.

LifeStance Health Group executive Ryan McGroarty reported an equity award of company stock. On March 5, 2026, he acquired 179,856 shares of common stock through a grant at a price of $0.00 per share, described as restricted stock units where each unit represents one share of common stock. Following this award, his directly held common stock holdings increased to 727,611 shares, including the newly granted RSUs, which vest into actual shares subject to their terms.

LifeStance Health Group, Inc. reported a large insider-related transaction involving entities affiliated with TPG. On March 2, 2026, an entity indirectly associated with the reporting persons completed an open-market sale of 20,685,061 shares of common stock at $7.01 per share. Following this sale, 140,026,557 shares of LifeStance common stock were reported as indirectly owned. According to the disclosures, the shares are directly held by TPG VIII Lynnwood Holdings Aggregation, L.P., and the reporting persons may be deemed to beneficially own the securities only to the extent of their respective pecuniary interests, which they expressly disclaim beyond that.

Entities affiliated with Summit Partners and associated with LifeStance Health Group director Darren M. Black sold 4,314,939 shares of LifeStance common stock in an open-market transaction at $7.01 per share. After these sales, the Summit-managed funds collectively held 29,209,776 LifeStance shares.

LifeStance Health Group, Inc. director filed a Form 4 reporting several sales of common stock through affiliated entities in December 2025. On 12/12/2025, Vitthal LLC and Shama LLC each sold 39,815 shares of LifeStance common stock at a weighted average price of $7.01 per share, with individual trades ranging from $7.00 to $7.045.

On 12/15/2025, Vitthal LLC sold 6,186 shares and Shama LLC sold 6,185 shares at a weighted average price of $7.00, with trades between $7.00 and $7.01. Following these transactions, the reporting person is shown as beneficially owning 1,382,175 shares indirectly through Vitthal LLC, 1,498,975 shares indirectly through Shama LLC, 57,619 shares directly, and 36,363 shares indirectly through Alpine Glow Capital, while disclaiming beneficial ownership beyond their pecuniary interests.

LifeStance Health Group, Inc. (LFST) disclosed that an executive sold company stock. On 11/21/2025, the Executive Vice President, Practice Operations reported selling 57,240 shares of LifeStance common stock at a weighted average price of $6.43 per share, in multiple trades between $6.41 and $6.50. After these sales, the executive beneficially owns 261,292 shares of LifeStance common stock. The filing notes that full trade details for each price within the range are available upon request.

LifeStance Health Group (LFST) reported an insider administrative transaction tied to RSU vesting. On November 10, 2025, an officer had 10,623 shares of common stock withheld at $6.43 per share to cover taxes from the net settlement of vested RSUs. The filing notes this was not an open‑market sale.

Following the transaction, the reporting person beneficially owned 318,532 shares directly. The individual is identified as Executive Vice President, Practice Operations.

LifeStance Health Group (LFST) reported a Form 4/A by its Chief People Officer correcting a prior filing. The amendment updates the number of shares withheld for taxes on PSUs vested on March 7, 2025 from 3,725 to 7,450, and updates holdings to 376,430 shares following the reported transactions.

Activity included: a grant of 76,142 RSUs on March 6, 2025; tax withholdings of 6,455 shares at $7.88 on March 6, 2025; PSU vestings of 27,740 and 32,052 on March 7, 2025; and additional tax withholdings of 7,450 shares at $7.59 and 8,606 shares at $7.59. The filing notes these withholdings reduce shares delivered and are not open‑market sales.